Skip to main content

Table 5 Distribution of antimicrobial senstivity according to the causing bacterial pathogen and pneumonia group

From: Increased antimicrobial resistance in bacterial pneumonia among Egyptian Children during the COVID-19 pandemic

Type

Organism

Antibiotics

%

CAP

S. pneumoniae

Linezolid

100

Vancomycin

85.7

Cefepime

71.4

Cefotaxime,Ceftriaxone

57.1

Co-trimoxazole

57.1

S. aureus

Linezolid

100

Vancomycin, Clindamycin,

80

Co-trimoxazole, Levofloxacin, Ciprofloxacin

60

H. influenzae

Colistin (Colistimethate Sodium)

66.6

Linezolid

66.6

Piperacillin-Tazobactam

66.6

Tigecycline

66.6

HAP

Klebsiella pneumoniae

Colistin (Colistimethate Sodium)

88.8

Tigecycline

44.4

Amikacin

33.3

Acinetobacter SPP

Colistin (Colistimethate Sodium)

100

Levofloxacin

75

Amikacin, Ciprofloxacin, Tigecycline

50

Pseudomonas aeruginosa

Colistin (Colistimethate Sodium)

100

Amikacin, Gentamicin, Ciprofloxacin, Levofloxacin, Imipenem-Cilastatin

33.3

E. Coli

Imipenem-Cilastatin, Colistin (Colistimethate Sodium), Tigecycline

100%

Gentamicin

 
  1. CAP Community-acquired pneumonia, HAP Hospital-acquired pneumonia